Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis

Abstract

Background

Multiple Sclerosis is associated with low serum levels of 25-hydroxyvitamin D (25(OH)D). We investigated the association between serum levels of 25(OH)D and 1,25-dihydroxyvitamin D (1,25(OH)2D), the biologically active metabolite, and clinical MS severity as expressed by EDSS-score and relapse rate.

Study-design

Cross-sectional study.

Patients and Methods

Serum samples from 267 MS patients were collected for 25(OH)D and 1,25(OH)2D measurement. Clinical MS parameters at the date of serum sampling were determined. Results: Both metabolite levels were significantly lower in the progressive forms compared to the relapsing remitting (RR)MS phenotype. In RRMS patients (disease course ≤ 5 years), high 25(OH)D levels were associated with a high chance of remaining relapse-free. Low 25(OH)D levels were associated with high EDSS-scores. 1,25(OH)2D was not directly associated with relapse rate or EDSS-score, and was dependent of age and 25(OH)D level.

Conclusion

Serum levels of 25(OH)D were associated with both relapse rate and disability in MS patients. These results are suggestive for a disease modulating effect of the serum concentrations of 25(OH)D on MS. The low circulating 1,25(OH)2D levels in progressive MS are due to older age and lower 25(OH)D levels. The potential consequences for vitamin D supplementation in MS will be discussed.

Keywords

1,25-dihydroxyvitamin D 25-hydroxyvitamin D multiple sclerosis vitamin D

Get full access to this article

View all access options for this article.

References

1 Compston A Confavreux C Lassmann H . McAlpine's Multiple Sclerosis. 4th ed. Churchill Livingstone, Elsevier, London, UK; 2006.

2 Smolders J Damoiseaux J Menheere P Hupperts R . Vitamin D as an immune modulator in multiple sclerosis, a review. J Neuroimmunol 2008; 194: 7–17.

3 Jongen MJ van der Vijgh WJ Lips P Netelenbos JC . Measurement of vitamin D metabolites in anephric subjects. Nephron 1984; 36: 230–234.

4 Lemire JM Archer DC . 1,25-dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. J Clin Invest 1991; 87: 1103–1107.

5 Cantorna MT Hayes CE DeLuca HF . 1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci U S A 1996; 93: 7861–7864.

6 Spach KM Hayes CE . Vitamin D3 confers protection from autoimmune encephalomyelitis only in female mice. J Immunol 2005; 175: 4119–4126.

7 Munger KL Levin LI Hollis BW Howard NS Ascherio A . Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006; 296: 2832–2838.

8 van der Mei IA Ponsonby AL Dwyer T . Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia. J Neurol 2007; 254: 581–590.

9 Soilu-Hanninen M Airas L Mononen I Heikkila A Viljanen M Hanninen A . 25-Hydroxyvitamin D levels in serum at the onset of multiple sclerosis. Mult Scler 2005; 11: 266–271.

10.

10 Soilu-Hanninen M Laaksonen M Laitinen I Eralinna JP Lilius EM Mononen I . A longitudinal study of serum 25-hydroxyvitamin D and intact PTH levels indicate the importance of vitamin D and calcium homeostasis regulation in multiple sclerosis. J Neurol Neurosurg Psychiatry 2008; 79: 152–157.

11.

11 Mahon BD Gordon SA Cruz J Cosman F Cantorna MT . Cytokine profile in patients with multiple sclerosis following vitamin D supplementation. J Neuroimmunol 2003; 134: 128–132.

12.

12 Barnes MS Bonham MP Robson PJ . Assessment of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D3 concentrations in male and female multiple sclerosis patients and control volunteers. Mult Scler 2007; 13: 670–672.

13.

13 Wingerchuk DM Lesaux J Rice GP Kremenchutzky M Ebers GC . A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 2005; 76: 1294–1296.

14.

14 Achiron A Barak Y Miron S Izhak Y Faibel M Edelstein S . Alfacalcidol treatment in multiple sclerosis. Clin Neuropharmacol 2003; 26: 53.

15.

15 McDonald WI Compston A Edan G . Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121–127.

16.

16 Dawson-Hughes B Heaney RP Holick MF Lips P Meunier PJ Vieth R . Estimates of optimal vitamin D status. Osteoporos Int 2005; 16: 713–716.

17.

17 Vieth R . The role of vitamin D in the prevention of osteoporosis. Ann Med 2005; 37: 278–285.

18.

18 Calabresi PA Austin H Racke MK . Impaired renal function in progressive multiple sclerosis. Neurology 2002; 59: 1799–1801.

19.

19 Nieves J Cosman F Herbert J Shen V Lindsay R . High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis. Neurology 1994; 44: 1687–1692.

20.

20 Kimball SM Ursell MR O'Connor P Vieth R . Safety of vitamin D3 in adults with multiple sclerosis. Am J Clin Nutr 2007; 86: 645–651.